Research
Hormonal
BPD permanently normalizes serum glucose and cholesterol in diabetic and hypercholesterolemic patients through specific metabolic actions independent of weight loss.
BPD can cure type 2 diabetes and high cholesterol through specific hormonal and metabolic changes in the gut, not just by losing weight. Many patients see normal blood sugar and cholesterol levels within a month of surgery, often allowing them to stop medications entirely.
GoodSupportsHIGH confidence
Beneficial effects other than those consequent to weight loss or reduced nutrient absorption included permanent normalization of serum glucose and cholesterol without any medication and on totally free diet in 100% of cases, both phenomena being due to a specific action of the operation.
Why this rating
Large cohort data (1773 patients) with 100% normalization rates for specific subgroups, supported by mechanistic studies.
Source
Biliopancreatic Diversion
Nicola Scopinaro et al. · World Journal of Surgery · 1998
DOI 10.1007/s002689900497
cohort · n=1356Cited 555×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Biliopancreatic diversion (BPD) achieves sustained weight loss and maintenance primarily by establishing a fixed intestinal energy absorption threshold for fat and starch, rather than through caloric restriction or reduced appetite.Good
- BPD induces a specific increase in resting energy expenditure (REE) driven by intestinal adaptation (increased bowel mass and activity), which contributes to weight loss independent of the absorption threshold.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →